In This Section
Dr. Hogarty is a pediatric oncologist with 20 years' experience as a physician-scientist with a careerlong focus on neuroblastoma translational biology.
Dr. Hogarty's research focuses on the childhood tumor neuroblastoma. Laboratory-based and translational in focus, his research involves using complementary preclinical models to identify the principal pathways used during in the initiation and progression of this cancer, and to better understand the cell’s behaviors and vulnerabilities. His ultimate goal is to translate discoveries in the lab and clinic toward the development of novel treatment approaches for neuroblastoma.
Dr. Hogarty's research focuses on three main areas, the first being how neuroblastoma cells survive all of the stressors they encounter during tumor growth and in response to treatment. Along with his colleagues, Dr. Hogarty developed a unique functional assay to identify the specific stress vulnerabilities for a cancer cell, and used this to select tumors for selective Bcl-2-directed treatments and to study the mechanisms of treatment resistance in general. The emergence of treatment resistance in tumor cells remains a major problem in neuroblastoma.
He is also interested in how the MYCN oncogene drives tumor progression. His work in this area tests numerous polyamine antagonists to see which combinations are most capable of reducing cancer cell polyamines and, importantly, which are most potent in regressing and curing neuroblastomas. To this end Dr. Hogarty employs complementary models using both xenograft-bearing and transgenic tumor-prone mice.
In addition, Dr. Hogarty and his colleagues discovered a novel oncogenic driver pathway in neuroblastoma using whole genome sequencing. Recurring mutations and deregulation in the BAF (Brg1-associated Factors) chromatin remodelling complex are associated with aggressive neuroblastoma behavior. The team is characterizing the function of this pathway in this tumor, how the mutations specifically alter this, and working to develop clinically useful assays to detect such mutations and even target them therapeutically.
Education and Training
BES, Johns Hopkins University (Biomedical Engineering), 1986
MD, Columbia University, 1990
Fellowship, Children's Hospital of Philadelphia (Pediatric Hematology/Oncology), 1997
Titles and Academic Titles
Associate Director, Pediatric Hematology/Oncology Fellowship
Professor of Pediatrics
American Association for Cancer Research
American Society of Clinical Oncology
American Society of Pediatric Hematology/Oncology
Children's Oncology Group
American Board of Pediatrics
International Histiocyte Society
Society for Pediatric Research
Young Investigator Award, American Society of Clinical Oncology, 1996
Young Investigator Award, Advances in Neuroblastoma Research, 1998
Molecular Approach to Pediatric Science-CHRC Award, 1998
Career Development Award, American Society of Clinical Oncology, 1999
Career Award in the Biomedical Sciences, Burroughs Wellcome Fund, 2000
University Research Foundation Award, 2005
Foerderer-Murray Research Award, 2005
Basic Science Award, Advances in Neuroblastoma Research, 2014